Targeted Therapy’s Skin Toxicities after Immunotherapy: Skin Toxicity of Tyrosine Kinase Inhibitor Therapy Following Nilovumab Therapy for Metastatic Renal Cell Carcinoma

Benjamin Verret, Cécile Badoual, Pierre Combe, Agnes Carlotti and Stephane Oudard

Hôpital Européen Georges Pompidou, Oncology Department, 20 rue Leblanc 75015 Paris
Hôpital Européen Georges Pompidou, Anatomopathology Department, 20 rue Leblanc, 75015, Paris
Université Paris Descartes, Paris
Hôpital Cochin, Anatomopathology Depatment, 27-30 Faubourg Saint Jacques, 75014 Paris, France

^*Correspondance to: Stephane Oudard 

 PDF  Full Text Case Report | Open Access

Abstract:

Anti-programmed cell death antibodies (anti-PD-1) are currently under development for the treatment of Metastatic Renal Cell Carcinoma (mRCC) and safety of subsequent treatment by VEGFR Tyrosine Kinase Inhibitors (TKI) is not known. We report two cases of unexpectedly severe skin rashes occurring on initiation of treatment by the tyrosine kinase inhibitor sorafenib after prior treatment with the anti-PD-1 nivolumab. Attention is drawn to the potential skin toxicity of TKI treatment after anti-PD-1 administration.

Keywords:

Immunotherapy; Anti-pd1; Nivolumab; Sorafenib; Renal cell carcinoma; Skin rashes; Drugs sequence

Cite the Article:

Verret B, Badoual C, Combe P, Carlotti A, Oudard S. Targeted Therapy’s Skin Toxicities after Immunotherapy: Skin Toxicity of Tyrosine Kinase Inhibitor Therapy Following Nilovumab Therapy for Metastatic Renal Cell Carcinoma. Clin Oncol. 2016; 1: 1133.